Sharipov, R.A.,
Omarov, M.A.,
Mulyukov, A.R.,
Dybova, A.I.,
Vyaseleva, E.T.,
Kayumova, N.B.,
Saitgalina, A. Sh.,
Ententeev, K.R.,
Iagafarov, I.R.,
Kuserbaev, I.V.,
Gubaeva, E.A. (2023) provides prospects for the treatment of many neurodegenerative diseases and
cancers that were previously
Gareev, Ilgiz,
Beylerli, Ozal,
Tamrazov, Rasim,
Ilyasova, Tatiana,
Shumadalova, Alina,
Du, Weijie,
Yang, Baofeng (2023) the primary research pathways in the development of new anti-
cancer medications, with a particular focus
Gareev, Ilgiz,
Encarnacion Ramirez, Manuel de Jesus,
Nurmukhametov, Renat,
Ivliev, Denis,
Shumadalova, Alina,
Ilyasova, Tatiana,
Beilerli, Aferin,
Wang, Chunlei (2023) for their involvement in the development and progression of various
cancers, including glioma. The dysregulation of lnc
Wu, Hongjie,
Beylerli, Ozal,
Gareev, Ilgiz,
Beilerli, Aferin,
Ilyasova, Tatiana,
Talybov, Rustam,
Sufianov, Albert,
Guo, Xiaolong (2023) determined. Up to 30% of adult patients with
cancer of one localization or another suffer from a secondary